The Flaviviridae family of enveloped, positive sense RNA viruses includes many important pathogens of the flavivirus genus. Particularly, Zika virus and Dengue virus, are expanding in geographic range, transmission intensity, and disease severity.
Ennaid’s anti-flavivirus technology is the result of a collaboration between Ennaid Therapeutics, Florida Gulf Coast University, and the University of Washington. Modified peptide-based inhibitors of the Zika and Dengue entry and infection process have shown inhibition in preliminary studies. Ennaid’s antiviral technologies are currently in animal trials, and safety and efficacy studies are being fast-tracked to accelerate new drug approval.